Scientific Advisory Board

Andreas Kremer, MD, PhD

Andreas Kremer, MD, PhD is Clinician Scientist and Professor of Hepatology in Zurich and lead investigator for multiple clinical trials whose expertise spans autoimmune and cholestatic liver disease, liver fibrosis, hepato- and cholangiocellular carcinoma, the gut-liver-axis and has high expertise in pruritus and fatigue.Paul Richardson, MD

John Lambert, PhD

John Lambert, PhD is one of the leading experts in the field of ADC discovery and development. He joined ImmunoGen in 1987 and served as Chief Scientific Officer from 2008 until 2015 and was subsequently Distinguished Research Fellow at ImmunoGen. During his tenure in leadership roles, ImmunoGen invented the antibody-drug conjugate technology that resulted in KADCYLA® (Genentech/Roche) and ELAHERE® (ImmunoGen, now AbbVie), for treatment of HER2+ breast cancer and platinum-resistant ovarian cancers respectively. He is the author/co-author of over 125 peer-reviewed scientific publications. He is a fellow of the American Institute for Medical and Biological Engineering (AIMB) and an Honorary Professor of Queen’s University, Belfast, Northern Ireland, UK.

Alan Bonder, MD, AGAF

Alan Bonder, MD, AGAF is Associate Professor of Medicine at Harvard University Medical School and Medical Director of Liver Transplant at Beth Israel Deaconess Medical Center in Boston; his expertise spans chronic liver diseases including cholestatic liver diseases including PBC and non-cholestatic liver diseases with expertise in patient care, clinical trials and pruritis associated with these conditions.

Vaughn Smider, MD, PhD

Vaughn Smider, MD, PhD is the founder and President of the Applied Biomedical Science Institute (ABS) and is an adjunct Professor at the Scripps Research Institute. Dr. Smider has multiple publications in antibody molecular biology, genetics, and structure, as well as in DNA repair and cancer biology. In these fields he also developed several groundbreaking technologies and was a founder and CSO of Fabrus, Taurus Biosciences (now part of Ligand’s spin-out company, OmniAb Inc. (NASDAQ: OABI), and ABS Institute spin-out companies Minotaur Therapeutics and Enkefalos Biosciences and serves as an advisor to several biotechnology companies.
The Company previously announced sufficient funding to extend its cash runway into early 2025 for a phase 2 clinical readout of its lead program, TH104. Tharimmune plans to advance both its clinical and non-clinical programs and will announce an R&D update in 2024.

Kwok-Kin Wong, MD, PhD – NYU School of Medicine

Dr. Wong is the Chief of Hematology and Medical Oncology at The Perlmutter Cancer Center at NYU Langone Medical Center. During his distinguished career, Dr. Wong served in various investigative and leadership roles at Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Harvard Medical School. His work has been published in over 250 scientific publications, and his world-renowned research has provided new insight into genetic and environmental causes of lung cancer, enabling novel lung cancer therapies. Currently, Dr. Wong continues his investigative pursuits, in to developing novel therapeutic strategies for small cell and non-small cell lung cancer. He received both his PhD and MD from Columbia University, completed his residency at Massachusetts General Hospital, and was a fellow at the Dana-Farber Cancer Institute.

Joseph Paul Eder, MD – Yale University/Yale Cancer Center

Dr. Eder is the Clinical Director of the Early Drug Development Program, performing Phase I clinical trials of new cancer medicines. He was previously the Clinical Director of the Experimental Therapeutics Program for the Dana-Farber/Harvard Cancer Center and had responsibility for the trials performed at the DF/HCC. These clinical and basic research activities have involved collaboration with clinical and basic scientists at Harvard and elsewhere, the Cancer Therapy Evaluation Program of the National Cancer Institute, presentations at national and international meetings, and correspondence with a number of leaders in the field of cancer drug development.

Paul Richardson, MD – Dana-Farber Cancer Institute/Harvard

Dr. Richardson is Corman professor of Medicine at Harvard medical School and serves as Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center and has led several novel, biologically-derived translational efforts in multiple myeloma. He holds numerous advisory board positions and is a member of dozens of professional organizations. In addition, he has published hundreds of original papers, reviews, chapters, and monographs in many leading peer-reviewed publications including The New England Journal of Medicine, Blood, and Journal of Clinical Oncology and many others. Dr. Richardson has led the study and clinical development of numerous novel drugs in the treatment of multiple myeloma which have contributed to improvement in outcome for patients.

Scott J. Dixon Ph.D. – Stanford University

Dr. Dixon obtained a Ph.D. in molecular genetics from the University of Toronto and is currently an Associate Professor in the Department of Biology at Stanford University. Dr. Dixon is a pioneer in the investigation of non-apoptotic cancer cell death, having spearheaded the discovery of ferroptosis and related iron-dependent cell death mechanisms. His laboratory is focused on detailed characterization of small molecule mechanism of action in cancer, with a view to discovering novel treatments for various indications.

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company’s lead clinical-stage asset, TH104, has been observed to suppress chronic, debilitating pruritus or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure. The Company’s early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company’s antibody discovery technology platform against these and other specified targets.

Tharimmune Inc.

Investors Menu